Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Epublish 8 citations
PubMed: 38500722 DOI: 10.3389/fpubh.2024.1321173
Predictors of seasonal influenza and COVID-19 vaccination coverage among adults in Tennessee during the COVID-19 pandemic.
Front Public Health 12:1321173
Authors: J Cunningham-Erves, W George, M Sanderson, E Stewart, S W Jin, J Davis, H M Brandt
Affiliations
- Department of Internal Medicine, School of Medicine, Meharry Medical College, Nashville, TN, United States.
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, United States.
- Department of Family and Community Medicine, School of Medicine, Meharry Medical College, Nashville, TN, United States.
- School of Social Work, The University of Memphis, Memphis, TN, United States.
- Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN, United States.
- St. Jude Children's Research Hospital, Department of Epidemiology and Cancer Control, Memphis, TN, United States.
Abstract
Background
The COVID-19 pandemic has convoluted hesitancy toward vaccines, including the seasonal influenza (flu) vaccine. Because of COVID-19, the flu season has become more complicated; therefore, it is important to understand all the factors influencing the uptake of these vaccines to inform intervention targets. This article assesses factors related to the uptake of influenza and COVID-19 vaccines among adults in Tennessee.
Methods
A cross-sectional, secondary data analysis of 1,400 adults was conducted in Tennessee. The adult sample came from two data sources: Data source 1 completed a baseline survey from January to March 2022, and data source 2 was completed from May to August 2022. Data on vaccine attitudes, facilitators and barriers, and communication needs were collected via random digit dial by Scientific Telephone Samples (STS). Two multivariable logistic regression models were used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) to predict sociodemographic and overall vaccine-related factors associated with receipt or non-receipt (referent) of COVID-19 and influenza vaccines.
Results
Approximately 78% of the adult sample had received the COVID-19 vaccination. A significant positive association for COVID-19 vaccine uptake was seen among those who were older (aged 50-65) (aOR = 1.9; 95% CI: 1.2-3.2), Black (aOR = 2.0; 95% CI:1.3-2.8), and had a college education and higher (aOR = 2.3; 95% CI: 1.5-3.6). However, there was a significant negative association for persons reporting they were extremely religious (aOR = 0.5; 95% CI:0.3-0.9). Over 56% of the adult sample had received the influenza vaccination this season. Those who had a higher annual household income (80,000+) (aOR = 1.9; 95% CI: 1.3-2.6) and had health insurance (aOR = 2.6; 95% CI: 1.4-4.8) had a significant positive association with influenza vaccine receipt. However, those who were employed part-time or were unemployed had a significant negative association for influenza vaccine receipt (aOR = 0.7; 95% CI: 0.5-0.9). Both COVID-19 and influenza vaccine receipt had strongly significant positive trends with increasing belief in effectiveness and trust ( < 0.0001) and strongly significant negative trends with higher levels of overall vaccine hesitancy ( < 0.0001).
Conclusion
Strategies to increase COVID-19 and influenza vaccination should be age-specific, focus on increasing geographical and financial access, and offer tailored messages to address concerns about these vaccines.
MeSH
Coronavirus, Vaccines, Covid-19 Vaccines, Public Health, Vaccination, Covid-19, Influenza, Human, Influenza Vaccines, Pandemics, Vaccination Coverage
Cited by
- Investigating the influencing factors of vaccination decisions for newly developed and established vaccines: a comparative study based on latent class logit models in China. Front Public Health, 2024
- Visual analysis of the research frontiers, hotspots and development trends of immunization programs for women and children. Hum Vaccin Immunother, 2025